Overview

Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614)

Status:
Terminated
Trial end date:
2013-03-20
Target enrollment:
Participant gender:
Summary
This is a study to determine the pharmacokinetics (PK) and weight-based dose of boceprevir following single oral dose administration in Chronic Hepatitis C Virus (HCV) pediatric participants.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.